

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/805,838 Confirmation No. 1494  
Applicant : Miller et al.  
Filed : March 22, 2004  
Title : CHEMILUMINESCENT COMPOUNDS AND USE THEREOF  
  
TC/A.U. : 1600/1645  
Examiner : HAQ, S.  
  
Docket No. : A1514-DIV  
Customer No. : 33197

## CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being transmitted via facsimile to  
Mail Stop AMENDMENT, Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450, to fax number 703-872-9306, on the date  
indicated below.

---

July 5, 2005

---

---

*/Greg S. Hollrigel, Reg. # 45374/  
Greg S. Hollrigel*

---

LETTER TRANSMITTING TERMINAL DISCLAIMER

Dear Sir:

Submitted herewith is a Terminal Disclaimer in the above-identified application. The  
Commissioner is hereby authorized to charge the necessary fee of \$130.00 (37 CFR 1.20(d)) to  
Deposit Account No. 13-5135.

Respectfully submitted,

Date: July 5, 2005

*/Greg S. Hollrigel, Reg. # 45374/  
Greg S. Hollrigel  
Registration No. 45,374  
Stout, Uxa, Buyan & Mullins, LLP  
4 Venture, Suite 300  
Irvine, California 92618  
(949) 450-1750  
(949) 450-1764 Facsimile*

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.	:	10/805,838	Confirmation No.	1494
Applicant	:	Miller et al.		
Filed	:	March 22, 2004		
Title	:	CHEMILUMINESCENT COMPOUNDS AND USE THEREOF		
TC/A.U.	:	1600/1645		
Examiner	:	HAQ, S.		
Docket No.	:	A1514-DIV		
Customer No.	:	33197		
Mail Stop AMENDMENT		07/06/2005 TL0111 00000009 135135 10005838		
Commissioner for Patents		01 FC:1814 130.00 DA		
P.O. Box 1450				
Alexandria, VA 22313-1450				

TERMINAL DISCLAIMER

Sir:

Your petitioner, Quest Diagnostics Investments, Inc., having a place of business at 300 Delaware Avenue, Wilmington, Delaware, by its practitioner, Greg S. Hollrigel, of record in the above-identified application, represents that it is the assignee, as shown by the assignment recorded in the Patent and Trademark Office on March 22, 2004, at Reel 015131, Frame 0581, of the entire right, title and interest in and to the above-identified application.

Pursuant to 37 CFR 3.73(b), your petitioner, as assignee of the above-identified application, hereby states that the above-noted assignment, the evidentiary document on which ownership of the above-identified application is established, has been reviewed. Further, your petitioner hereby certifies that, to the best of your petitioner's knowledge and belief, title to the above-identified application is in your petitioner, as assignee seeking to take the action in this Terminal Disclaimer.

Your petitioner, Quest Diagnostics Investments, Inc., hereby disclaims the terminal part of any United States patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term as presently shortened by any terminal disclaimer of United States Patent No. 6,723,851, and hereby agrees that any United States

Appl. No. 10/805,838  
Terminal Disclaimer

2

patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to such patent shall be the same as the legal title to United States Patent No. 6,723,851, this agreement to run with any patent granted on the above-identified application and be binding upon the grantee, its successors or assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimer of United States Patent No. 6,723,851 in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

Date: July 5, 2005

/Greg S. Hollrigel, Reg. # 45374/  
Greg S. Hollrigel  
Registration No. 45,374  
Stout, Uxa, Buyan & Mullins, LLP  
4 Venture, Suite 300  
Irvine, California 92618  
(949) 450-1750  
(949) 450-1764 Facsimile